GeneDx is trading at $63.00 (-10.28%), with no clear company-specific catalyst identified for the October 16 decline. - Coverage described the early drop as occurring on light volume. - Broader risk-off pressure offered context: biotech sector ETF XBI fell 2.06%, while major U.S. indexes also moved lower. GeneDx’s decline was substantially steeper, so market weakness may be a contributor, not a complete explanation. - A CEO share sale reported October 16 occurred on September 16 and does not establish a same-day catalyst.